Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Prof. Dr. Oliver Krüger is a behavioral ecologist and evolutionary biologist at Bielefeld University 's Faculty of Biology , where he leads the Department of Animal Behaviour since 2013. His research spans avian and marine mammal systems, focusing on life history strategies, parasite-host interactions, and environmental adaptation. Education: Biology studies at Bielefeld University (1994-1996) MSc in Oxford (1996-1997) PhD at Bielefeld University with Fritz Trillmich and Jan Lindström (1998-2000) Research Themes: Behavioral ecology, evolutionary biology, and population dynamics across tropical and temperate ecosystems. Key projects include NC³ (Niche Choice/Construction) and studies on Galápagos sea lions, common buzzards, and pinniped species. Scientific Leadership: Spokesperson, SFB TRR 212 "NC³" (2018-2025) Advisory Board member: German Ornithologists Union, IUCN SSC pinniped group, German Primate Centre Peer review roles: Humboldt Foundation, DFG, HFSP, NSF Awards: Leopoldina Prize (2001) Niko Tinbergen Award (2008) DFG Heisenberg Professorship (2010-2015)
Prof. Ralph Hückelhoven is a Professor of Phytopathology at the Technical University of Munich (TUM), affiliated with the TUM School of Life Sciences. His research focuses on the molecular and biological mechanisms underlying plant diseases, particularly plant immunity, pathogen exploitation of signal transduction, and host-pathogen interactions. He leads the Chair of Phytopathology at TUM since 2006, following academic roles at universities of Kiel and Hohenheim. Education: PhD (1999) and habilitation in molecular phytopathology (2005) from Justus Liebig University Giessen, after a biology degree at RWTH Aachen University. Awards: Julius Kühn Prize (2004) and leadership of a DFG Junior Research Group (2002-2006). His research spans plant immunity at cellular and molecular levels, including studies on receptor kinases (e.g., MIK2, LORE), RAC GTPases (e.g., RACB), and metabolomics-driven insights into pathogen resistance. He has published over 100 peer-reviewed articles, examining topics like fungal toxins, volatile signaling, and crop disease management. Key publications include work on Arabidopsis immune receptors, barley powdery mildew susceptibility factors, and Fusarium head blight resistance. Research integrates genetics, proteomics, and metabolomics to advance disease-resistant crop development. His lab investigates host-pathogen interactions across scales—from molecular signaling to field epidemiology—contributing to sustainable agricultural strategies against plant pathogens.
Prof. Dr. Michael Schloter serves as Director of the Research Unit for Comparative Microbiome Analysis at Helmholtz Munich since 2011 and holds a Professorship in Microbiology at the Technical University of Munich since 2010. He concurrently acts as Principal Investigator at both the German Center for Lung Diseases (DZL) and the Central for Food and Nutrition (ZIEL) at TU Munich, driving interdisciplinary research at the intersection of environmental and human health through the "Planetary Health" framework. His educational foundation was built through diploma studies at Ludwig Maximilian University Munich and doctoral research at the University of Bayreuth, followed by formative work in Brazil and the United States where he pioneered bioinocula development for stress-resilient agriculture. At Helmholtz Munich (formerly GSF), he evolved from group leader in soil microbial ecology (2001) to Research Unit Director, expanding his focus from agricultural systems to human microbiome-health connections. Dr. Schloter's research program centers on microbiome-host crosstalk across ecological scales, investigating how environmental microbiota interact with human and plant microbiomes to influence health outcomes. His work integrates ecological theory with microbiome analysis to decode host-microbe co-evolution patterns, with applications spanning sustainable agriculture, allergy prevention, and infection control. Key thematic pillars include holobiont theory, probiotic development, and microbiome-mediated disease prevention through environmental quality improvement. Analysis of his 2025 publications reveals a strategic research portfolio bridging fundamental and applied microbiome science. Agricultural studies dominate (maize, potato, apple systems), examining microbial inoculants and soil management, while human health investigations explore preterm birth complications and Antarctic mammal microbiomes. Computational approaches for antimicrobial resistance assessment and ecosystem-scale projects like JenaTron demonstrate methodological breadth, all converging on translating microbiome functionality into real-world sustainability solutions. Major recognitions include: Election to the Bavarian Academy of Science (2021) Consistent placement among the top 1% of highly cited global researchers (2019-2021) Heinrich Baur Research Award (2011) for agricultural microbiology contributions As Research Unit Director, Schloter leads large-scale collaborative initiatives including the DZL and ZIEL consortia, securing major funding for microbiome standardization projects and international research networks. His leadership extends to developing analytical frameworks for cross-ecosystem microbiome comparisons and establishing protocols for translating microbial ecology principles into clinical and agricultural applications. The Comparative Microbiome Analysis unit operates as a nexus for multi-host microbiome research, employing comparative genomics, field-scale agricultural trials, and clinical cohort studies to investigate microbiome dynamics across environmental, plant, and human systems. Current infrastructure includes advanced sequencing facilities and experimental platforms for plant-microbe and host-microbe interaction studies under controlled and natural conditions.
Martin Kaltenpoth serves as Director at the Max Planck Institute for Chemical Ecology in Jena since 2020 and Professor for Evolutionary Ecology at Johannes Gutenberg University of Mainz since 2015. Previously, he led the Research Group Insect Symbiosis at the MPI for Chemical Ecology from 2009 to 2015. Education: PhD in Biology (summa cum laude), University of Würzburg, 2006 Diploma in Biology (with honors), University of Würzburg, 2003 His research centers on insect-bacterial symbioses , investigating evolutionary, ecological, and chemical dimensions of host-microbe interactions. Key foci include nutritional and defensive symbiosis in beetles, genomic adaptations of symbiotic bacteria, and chemical mediation of symbiotic relationships. His work bridges entomology, microbiology, and chemical ecology to unravel coevolutionary mechanisms. Analysis of recent publications reveals dominant trends in beetle-microbe systems, emphasizing symbiont roles in cuticle synthesis, antifungal defense, and host-plant adaptation. His studies frequently employ genomic, biochemical, and experimental approaches across diverse insect lineages. No scientific awards were documented in the source material. While specific advisees and grants remain unlisted, his leadership of research groups and dual academic appointments indicate active supervision of graduate researchers and externally funded projects in symbiosis evolution. Currently directing research at the Max Planck Institute, Kaltenpoth advances understanding of symbiotic systems with implications for evolutionary theory and sustainable pest management strategies.
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Michael T. Monaghan is a Professor at the Faculty of Biology, Chemistry and Pharmacy, Freie Universität Berlin, and leads the Research Group in Molecular Ecology and Genomics at the Leibniz Institute of Freshwater Ecology and Inland Fisheries (IGB). His work bridges evolutionary biology, molecular ecology, and environmental monitoring, focusing on freshwater systems and urban aquatic habitats. Education: B.S. (The Ohio State University, 1995), M.S. (Idaho State University, 1998), Dr. sc. nat. (ETH Zürich, 2002) Key Positions: Senior Scientist/Research Group Leader at IGB (2008–present), Visiting Professor at Duke-NUS Medical School (2016), Guest Professor at Ehime University (2015–2016) Dr. Monaghan's research explores freshwater biodiversity dynamics using molecular tools like metabarcoding and phylogenomics. His team investigates how environmental changes—climate warming, urbanization, pollution—affect microbial and insect communities, with a focus on eDNA applications and ecohydrology. His publications (2022–2025) span topics such as climate-driven plankton shifts, urban habitat adaptation by bees, toxin genetics in algae, and metagenomic monitoring of aquatic systems. Collaborative projects like BiNatUr and ODER~SO emphasize urban resilience and disaster ecology. Teaching includes data science in biology, evolutionary ecology, and environmental genomics at Freie Universität Berlin and the Institute of Computer Science. He mentors doctoral and master’s students in molecular ecology and trains interns in biodiversity genomics. Lab Members: Dr. Dagmar Frisch (Scientific Staff) Dr. Katrin Kiemel (Postdoc) Elisabeth Funke (Research Technician) Doctoral Candidates: Onur Erk Kavlak, Athena Karapli-Petritsopoulou, Daniel Wewer
Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.
Dr. Martin Lange is part of the Project Group Ecological Epidemiology within the Department of Ecological Modelling at the Helmholtz Centre for Environmental Research (UFZ). His research focuses on computational epidemiology, particularly in wildlife and livestock systems. Key areas include disease transmission dynamics, surveillance strategies, and the development of predictive models for infectious diseases like African Swine Fever (ASF) and Bovine Viral Diarrhea Virus (BVDV). Affiliations: UFZ, Department of Ecological Modelling; EcoEpi research group. Education: PhD in Veterinary Epidemiology (2013, TU Bergakademie Freiberg). Research interests span ecological epidemiology, wildlife disease control, and the application of agent-based and individual-based models to understand pathogen spread. Notable contributions include modeling ASF in wild boar populations and BVDV eradication strategies in Ireland. Awards: Received the 2018 UFZ-Wissenstransferpreis (shared with H.H. Thulke) and the Konrad-Bögel-Nachwuchsförderpreis for his doctoral work on eco-epidemiology of wild boar diseases. Also recognized at the DACh Epidemiologietagung 2011. Publications: Over 50 peer-reviewed articles since 2006, emphasizing interdisciplinary approaches to disease modeling and environmental systems. Recent work includes digital twin frameworks for biodiversity monitoring and Python-based model coupling tools like FINAM. Labs/Teams: Active in the EcoEpi group and contributes to projects like BioDT (Biodiversity Digital Twin) and CauSES (Causation in Social-Ecological Systems).
Jochen Wolf is Chair of the Evolutionary Biology Division at Ludwig-Maximilians-Universität München (LMU) and a Max Planck Fellow of the Max Planck Institute for Biological Intelligence since 2022. His research integrates evolutionary biology, genomics, and ecology to address fundamental questions about speciation, adaptation, and biodiversity across multiple biological systems. Dr. Wolf's research program applies an integrative approach to understand microevolutionary processes and genetic mechanisms underlying species divergence. His work combines large-scale genomic analyses with laboratory and field experiments to characterize genomic divergence across populations and species. Key empirical systems include natural populations of birds (particularly corvids, swallows, and cuckoos), marine mammals (pinnipeds and killer whales), plant communities, and experimental evolution in fission yeast. His research spans multiple scales from immediate microevolutionary processes to broader evolutionary patterns across time. His recent publications reveal a sophisticated integration of genomic, epigenetic, and ecological perspectives. A notable trend shows increasing focus on structural genomic variation, chromosomal rearrangements, and epigenetic mechanisms as drivers of evolutionary processes. His work demonstrates how these molecular mechanisms interact with ecological factors to shape patterns of biodiversity and adaptation. Dr. Wolf's research has gained significant recognition through publications in top-tier journals including Nature, Science, and Nature Ecology & Evolution. His groundbreaking studies on crow hybrid zones, killer whale ecotypes, and experimental evolution of speciation have been featured in prominent media outlets such as The New Yorker, The Guardian, Scientific American, and Der Spiegel, demonstrating the broad impact of his work. As Principal Investigator, Dr. Wolf actively mentors doctoral students and postdoctoral researchers, fostering the next generation of evolutionary biologists. His lab maintains strong international collaborations, particularly through affiliations with SciLifeLab in Uppsala. Research in his group is supported by multiple funding sources including German Research Foundation grants and European Union programs, enabling both fundamental research and applications to conservation biology. The Wolf lab operates within LMU's Division of Evolutionary Biology, which provides access to state-of-the-art facilities including the Leibniz Supercomputing Centre. The lab maintains strong connections with the Max Planck Institute for Biological Intelligence and SciLifeLab in Uppsala, creating a rich collaborative environment for interdisciplinary research in evolutionary genomics. This network enables comprehensive studies spanning from molecular mechanisms to ecological and evolutionary consequences across diverse biological systems.
Prof. Dr. Jörg Stülke is a full Professor of Microbiology and Head of the Department of General Microbiology at the Institute of Microbiology and Genetics, University of Göttingen. He has held this position since 2003 and leads an active research group focused on bacterial metabolism and gene regulation. His research spans two major model systems: the pathogenic bacterium Mycoplasma pneumoniae and the well-studied Bacillus subtilis . His group employs systems-level approaches including transcriptomics, metabolomics, and bioinformatics to understand metabolic regulation and gene expression. Key interests include protein phosphorylation, RNA-mediated regulation, mRNA processing, and the role of second messengers such as cyclic di-AMP in bacterial physiology and pathogenicity. The recent publications reveal a strong trend in molecular microbiology, functional genomics, and systems biology. His work often integrates experimental and computational methods, particularly evident in the development and maintenance of the SubtiWiki database for B. subtilis . The research bridges fundamental mechanisms of life with applications in understanding bacterial virulence and cellular homeostasis. He is affiliated with several graduate programs under the Göttingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB), including: Molecular Biology (IMPRS) Biomolecules: Structure - Function - Dynamics (GZMB) Molecular Biology of Cells (GZMB) Microbiology and Biochemistry Genome Science (IMPRS) While no individual students are listed, he clearly supervises doctoral candidates through these programs. His group has secured significant research output, including publications in Science , Nucleic Acids Research , and PLOS Pathogens , indicating successful grant funding and collaborative research. The lab maintains a dedicated website at http://genmibio.uni-goettingen.de/ , which serves as a hub for research activities and resources like SubtiWiki.
G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms
Univ.-Prof. Dr. med. Martin A. Kriegel serves as full Professor and Department Head of the Department of Translational Rheumatology and Immunology at the Institute of Musculoskeletal Medicine, University of Münster, while maintaining an active laboratory at Yale School of Medicine. He leads the Section for Rheumatology and Clinical Immunology (SRKI) at Medical Clinic D, where his team integrates clinical care with cutting-edge microbiome research. His department operates from Röntgenstraße 21 and Von-Esmarch-Str. 54 in Münster, Germany, with extensive collaborations including the "Cells in Motion" research initiative and the CiM-IMPRS graduate program. Dr. Kriegel's research program focuses on the critical interface between host immunity and microbiota, particularly investigating how gut commensals translocate to host tissues and trigger autoimmune responses. His laboratory pioneered the discovery that specific pathobionts like Enterococcus gallinarum and certain Lactobacillus strains can translocate from the gut to mesenteric lymph nodes, liver, and other sites, driving autoimmune responses through molecular mimicry of human autoantigens. His work has established fundamental mechanisms by which microbiota influence rheumatic diseases, cutaneous autoimmunity, and cancer immunology, with particular emphasis on Ro60 autoantigen mimicry, TLR7-dependent pathways, and diet-microbiome interactions. The laboratory employs advanced techniques including gnotobiotic mouse models, humanized systems, and detailed molecular characterization of host-pathobiont interactions. Analysis of Dr. Kriegel's publication record reveals a consistent trajectory of high-impact research connecting microbiome dynamics to autoimmune pathogenesis. His most recent work (2023-2025) demonstrates increasingly sophisticated understanding of how specific bacterial strains influence disease phenotypes across multiple autoimmune conditions, with notable advances in identifying shared microbiome signatures across lupus and inflammatory bowel disease. The publications show progressive refinement from initial observations of microbial translocation to detailed mechanistic insights into tryptophan catabolism pathways, structural basis of molecular mimicry, and diet-sensitive microbial triggers. Dr. Kriegel's scientific recognition includes US Patent No. 11,058,756 B2 for compositions treating autoimmune diseases by reducing enterococcus, reflecting the translational potential of his research. His laboratory receives substantial funding, most notably a $3 million award from the Lupus Research Alliance for the TransLuMi project investigating gut pathobiont translocation in systemic lupus erythematosus. As an educator and mentor, Dr. Kriegel directs a substantial research team including multiple postdocs (Drs. Marcia Pereira, Nathalie Becker), PhD candidates (Anna Brinkhege, Carina Brune, Helen Fuhrmann), and laboratory specialists. He participates in the CiM-IMPRS graduate program and supervises medical students through the MedK program. His laboratory currently manages multiple significant research projects including: (A) intestinal wall permeability and pathobiont translocation in autoimmunity; (B) diet-environment-microbiome interactions; (C) microbiota disruption of immunological tolerance; and (D) microbiome roles in lymphoma development. The Kriegel laboratory maintains state-of-the-art facilities at both Münster and Yale, with specialized capabilities in gnotobiotic research, microbiome analysis, and immune profiling. His team collaborates with international partners including Dr. Eran Elinav at Weizmann Institute, Dr. Nissan Yissachar at Bar-Ilan University, Prof. George Tsokos at Harvard, and Prof. Ilana Brito at Cornell University. The laboratory's website (https://www.medizin.uni-muenster.de/mikrobiom/startseite/) details ongoing projects and research opportunities.
